Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited…
ntinued expansion in both new and repeat prescribers for the recurrent pericarditis treatment. The company raised its full-year 2026 ARCALYST revenue guidance to a range of $980 million to $995 million, from its prior range of $930 million to $945 million
Kiniksa also announced dose-focusing data for KPL-387 and said the pivotal Phase III PASTEURAL trial is enrolling and dosing patients. “Kiniksa is in a strong position more than halfway through 2026 as we continue to execute across our portfolio,” CEO and Chairman Sanj Patel said. Patel said the company anticipates a potential commercial launch of KPL-387 in the 2028 to 2029 timeframe. ARCALYST Growth and Commercial Strategy Chief Operating Officer Ross Moat said the second quarter represented the largest quarterly increase in ARCALYST net revenue since the product’s launch more than five years ago.
He attributed the performance to the company’s commercial strategy, including investments in sales infrastructure, machine learning and artificial intelligence tools, direct-to-consumer outreach, and dissemination of clinical guidance. Kiniksa launched its targeted direct-to-consumer campaign, called Heart’s Home, in April. The campaign is designed to educate patients with recurrent pericarditis and encourage them to discuss ARCALYST with their healthcare providers.